drugset
drugset / Trial / NCT05357755

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

NCT05357755 ↗

Phase 2 Completed 90 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.

Timeline

Start
2022-06-13
Primary completion
2023-03-23
Completion
2023-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotrokinra Peptide — Oral

Indications

psoriasis